近日，来自德克萨斯大学的David S Hong教授团队于The New England Journal of Medicine杂志发表文章Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer，公布了索托拉西布在胰腺癌的一、二期临床研究结果，评估了索托拉西布针对KRAS p.G12C突变型胰腺癌治疗的安全性及有效性。研究对象涵盖了38位携带KRAS ...
Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene. The KRAS oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and it signaling ...
近日,来自德克萨斯大学的David S Hong教授团队于The New England Journal of Medicine杂志发表文章Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer,公布了索托拉西布在胰腺癌的一、二期临床研究结果,评估了索托拉西布针对KRAS p.G12C...
Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021 Feb;48(1):10-18. doi: 10.1053/j.seminoncol.2021.02.003. Epub 2021 Feb 23. PMID: 33676749; PMCID: PMC8380752. Yan H, Yu CC, Fine SA, Youssof AL...
"KRAS-G12R is unique in that it is a mutation that seems to only occur in pancreatic cancer and not in the other cancer types associated with KRAS mutations, such as lung cancer," said Dr. Chandwani, who is also a member of the Sandra and Edward Meyer Cancer Center and the Englander ...
[4] Wei Daoyan, Wang Liang, Zuo Xiangsheng, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res, 2023, undefined: undefined. [5] Prior Ian A, Hood Fiona E, Hartley James L. The Frequency of Ras Mutations in Cancer....
15. Luo J. KRAS mutation in pancreatic cancer. Semin Oncol 2021;48:10-8.16. Nakajima EC, Drezner N, Li X, et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 2022;28:1482-6. 发布于 2023-01-17 16:21・IP 属地广东...
期待KRAS G12D抑制剂领域早日实现重大突破,现阶段很多临床试验正在招募中,对于标准治疗失败或无标准治疗方案的患者或可通过临床试验获益,迎来新希望。 参考文献 [1] Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021 Feb;48(1):10-18. [2] https://clinicaltrials.gov/...
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. Journal:Target Oncol IF:4.036 PMID:32495162 概要: BRAF癌基因的驱动突变已被证明是治疗晚期黑色素瘤和结直肠腺癌的一个有效分子靶点,在3%的晚期胰腺导管腺癌患者中发现。本案例报道一例66岁晚期低分化...
Li, S., Balmain, A., & Counter, C. M. (2018). A model for RAS mutation patterns in cancers: finding the sweet spot. Nature Reviews Cancer, 18(12), 767–777. https://doi.org/10.1038/s41568-018-0076-6 Liu, P., Wang, Y., & Li, X. (2019). Targeting the untargetable KRAS...